Voltar
Revisão Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy

2018; Elsevier BV; Volume: 70; Issue: 5 Linguagem: Inglês

10.1016/j.jhep.2018.12.022

ISSN

1600-0641

Autores

Cihan Yurdaydìn, Zaigham Abbas, Marı́a Buti, Markus Cornberg, Rafael Esteban, Ohad Etzion, Edward Gane, Robert G. Gish, Jeffrey S. Glenn, Saeed Hamid, Theo Heller, Christopher Koh, Pietro Lampertico, Yoav Lurie, Michael P. Manns, Raymundo Paraná, Mario Rizzetto, Stephan Urban, Heiner Wedemeyer, A. Wranke, Lourdes Maria Pinheiro Borzacov, Cirley Lobato, Saeed Hamid, Emanoil Ceaușu, George Ν. Dalekos, Adela Turcanu, Grazia Anna Niro, Farheen Lubna, Minaam Abbas, Patrick Ingiliz, Péter Ferenci, Thomas Vanwolleghem, Tonya Hayden, Naranjargal Dashdorj, Adriana Moţoc, Svenja Hardtke,

Tópico(s)

Hepatitis Viruses Studies and Epidemiology

Resumo

Chronic hepatitis delta represents the most severe form of chronic viral hepatitis. The current treatment of hepatitis delta virus (HDV) infection consists of the use of interferons and is largely unsatisfactory. Several new compounds are currently in development for the treatment of HDV infection. However, surrogate markers that can be used to develop clinical endpoints in HDV infection are not well defined. In the current manuscript, we aimed to evaluate the existing data on treatment of HDV infection and to suggest treatment goals (possible “trial endpoints”) that could be used across different clinical trials.

Referência(s)